Cargando…

The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

Individual comorbidities have distinct contributions to nonrelapse mortality (NRM) following allogeneic hematopoietic cell transplantation (allo-HCT). We studied the impact of comorbidities individually and in combination in a single-center cohort of 573 adult patients who underwent CD34-selected al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shouval, Roni, Fein, Joshua A., Cho, Christina, Avecilla, Scott T., Ruiz, Josel, Tomas, Ana Alarcon, Sanchez-Escamilla, Miriam, Flores, Nerea Castillo, Yáñez, Lucrecia, Barker, Juliet N., Dahi, Parastoo, Giralt, Sergio A., Geyer, Alexander I., Gyurkocza, Boglarka, Jakubowski, Ann A., Lin, Richard J., O’Reilly, Richard J., Papadopoulos, Esperanza B., Politikos, Ioannis, Ponce, Doris M., Sauter, Craig S., Scordo, Michael, Shaffer, Brian, Shah, Gunjan L., Sullivan, James P., Tamari, Roni, van den Brink, Marcel R. M., Young, James W., Nagler, Arnon, Devlin, Sean, Shimoni, Avichai, Perales, Miguel-Angel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905694/ https://www.ncbi.nlm.nih.gov/pubmed/34507354 http://dx.doi.org/10.1182/bloodadvances.2021004319

Ejemplares similares

Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation
por: Nawas, Mariam T., et al.
Publicado: (2022)

Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy
por: Infante, Maria Stefania, et al.
Publicado: (2022)

Engraftment Kinetics after Transplantation of Double Unit Cord Blood Grafts Combined with Haplo-identical CD34+ Cells without Anti-thymocyte Globulin
por: Politikos, Ioannis, et al.
Publicado: (2020)

Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis
por: Eshel, Adi, et al.
Publicado: (2022)

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves
por: Nawas, Mariam T., et al.
Publicado: (2021)

Shouval R, Fein JA, Cho C, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6(5):1525-1535.
Publicado: (2022)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia
por: Fingrut, Warren B., et al.
Publicado: (2022)

Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection
por: Shah, Nishi, et al.
Publicado: (2022)

Racial disparities in access to alternative donor allografts persist in the era of “donors for all”
por: Fingrut, Warren B., et al.
Publicado: (2022)

Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study
por: Shouval, Roni, et al.
Publicado: (2016)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
por: Magen, Hila, et al.
Publicado: (2023)

P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
por: Geva, Mika, et al.
Publicado: (2023)

Fecal Microbiota Transplantation for Treatment of Acute Graft-versus-Host Disease
por: Shouval, Roni, et al.
Publicado: (2019)

Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis
por: Hermans, Sjoerd J. F., et al.
Publicado: (2023)

Regulatory T Cells in Allogeneic Stem Cell Transplantation
por: Michael, Maria, et al.
Publicado: (2013)

Antithymocyte globulin exposure in CD34(+) T-cell–depleted allogeneic hematopoietic cell transplantation
por: Lakkaraja, Madhavi, et al.
Publicado: (2022)

Humoral Response to COVID-19 Vaccination Given Pre-Cellular Therapy Wanes in Patients after Cellular Therapy: An Argument for Full Reimmunization
por: Shah, Gunjan L., et al.
Publicado: (2022)

Prospective geriatric assessment and geriatric consultation in CAR T-cell therapy for older patients with lymphoma
por: Lin, Richard J., et al.
Publicado: (2023)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Association between busulfan exposure and survival in patients undergoing a CD34(+) selected stem cell transplantation
por: Tamari, Roni, et al.
Publicado: (2023)

Personalized prediction of overall survival in patients with AML in non‐complete remission undergoing allo‐HCT
por: Hirabayashi, Shigeki, et al.
Publicado: (2021)

595. Letermovir (LTV) for Secondary Cytomegalovirus (CMV) Prevention in High Risk Hematopoietic Cell Transplant (HCT) Recipients: Interim Results of a Single Center, Open Label Study
por: Han, Gyuri, et al.
Publicado: (2021)

The post-transplant scoring system (PTSS) is associated with outcomes in patients with MDS after CD34+selected allogeneic stem cell transplant
por: Alarcon Tomas, Ana, et al.
Publicado: (2021)

1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
por: Danino, Dana, et al.
Publicado: (2019)

Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study
por: Ito, Ayumu, et al.
Publicado: (2021)

Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant
por: Prockop, Susan E., et al.
Publicado: (2023)

Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies
por: Horwitz, Mitchell, et al.
Publicado: (2023)

Make Your Cake and Eat It: Refueling of Immune Fitness in AML Post Allo-HCT Using Baking Soda
por: Tonks, Alex
Publicado: (2021)

Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study
por: Zecca, Marco, et al.
Publicado: (2019)

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering
por: Ye, Yishan, et al.
Publicado: (2022)

Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation
por: Nunez, Lina, et al.
Publicado: (2022)

Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation
por: Slavin, Thomas P., et al.
Publicado: (2019)

Respiratory Virus (RV) from Broncho Alveolar Lavage (BAL) Prior to Hematopoietic Cell Transplantation (HCT): A Strong Predictor for Allo-Immune Mediated Lung Syndromes (allo-LS)
por: Versluys, Birgitta, et al.
Publicado: (2015)

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes
por: Steinhardt, M. J., et al.
Publicado: (2020)

1077. Infectious complications after second allogeneic hematopoietic cell transplant (allo-HCT) in adult patients with hematological malignancies
por: Maurer, Stephen, et al.
Publicado: (2020)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation
por: Scordo, Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7uqc4lnc28i5j0atrofl5utcc7